PRINCETON, NJ — A new combination pill has been approved by the Food and Drug Administration for patients with an advanced form of colorectal cancer who are no longer responding to other therapies. Lonsurf, manufactured by Taiho Oncology Inc. in… Read More
JERSEY CITY, NJ – A new option for treating schizophrenia and bipolar disorder in adults has been approved by the Food and Drug Administration. The drug Vraylar, cariprazine in capsule form, is manufactured by Forest Laboratories LLC of Jersey City,… Read More
New Guidelines Significantly Different from AHA/ACC Document
FALLS CHURCH, VA – The DoD has successfully reversed a trend toward increased use of opioids by engaging pharmacists in oversight and management of polypharmacy patients in Warrior Transition Units.
Higher Pneumonia Vaccine Rates Urged By Brenda L. Mooney PROVIDENCE, RI – With influenza season each year comes an even greater challenge for VA hospitals — a spate of pneumonia cases in older veterans. Recent research suggests the problem will… Read More
Free Shots Available at Walgreen’s Locations By Annette M. Boyle SAN FRANCISCO – The VA typically has influenza vaccination rates well above the national average but is trying some innovative measures to do even better. As part of the effort to increase immunizations,… Read More
New Formulations Might Be More Effective By Annette M. Boyle BETHESDA, MD – In the last 50 years, the use of anticoagulants has transformed mortality rates for deep vein thrombosis (DVT), pulmonary embolism (PE) and atrial fibrillation, and new anticoagulants… Read More
By Annette M. Boyle BETHESDA, MD – Veterans on statins have another good reason to continue to take their medication, according to new research. Statins not only reduce cholesterol, combat cardiovascular disease and potentially reduce the risk of prostate cancer,… Read More
By Brenda L. Mooney DALLAS – The suspected link between azithromycin and an increased incidence of cardiovascular events was borne out in a recent VA study of veterans hospitalized with pneumonia, but that was only part of the story: The… Read More
By Annette M. Boyle MILWAUKEE – Many patients prefer the devil they know. When asked whether they want to go on or switch to a novel oral anticoagulant (NOAC) that requires little monitoring, has few drug-drug or food interactions, appears… Read More
By Annette M. Boyle
TAMPA ‑ What price safety?
An estimated 5-10% of all cutaneous T-cell lymphoma (CTCL) diagnosed each year occurs in veterans treated by the VA. The cancer, classified as presumptively caused by Agent Orange exposure, is notoriously difficult to diagnose and often tricky to treat. That… Read More
By Annette M. Boyle DURHAM, NC — Women initially diagnosed with metastatic breast cancer have only a 23% overall five-year survival rate — and will spend most of their lives battling their cancer with a series of chemotherapies that might… Read More
WASHINGTON — The consolidation of 10 functions that have been performed separately by the Army, Navy and Air Force under the Defense Health Agency is projected to save $2 billion by 2019.
TITUSVILLE, NJ — Food and Drug Administration approval of Topamax (topiramate) for migraine headaches prophylaxis has been extended to adolescents ages 12 to 17. It was the first FDA approval of a drug for migraine prevention in this age group.… Read More
MONTREAL — The Food and Drug Administration has approved Impavido, for the tropical disease leishmaniasis, which has plagued U.S. troops deployed to areas such as Iraq. Leishmaniasis is caused by Leishmania, a parasite which is transmitted to humans through sand… Read More
SUMMIT, NJ — Clinicians have a new tool in their arsenal to treat active psoriatic arthritis. The Food and Drug Administration recently approved Otezla (apremilast) to treat adults with active psoriatic arthritis (PsA). The drug is marketed by Celgene Corporation,… Read More
Highest Customer Satisfaction for Fourth Year in A Row By Annette M. Boyle MILWAUKEE — For the fourth year in a row, the VA’s Consolidated Mail Outpatient Pharmacy (CMOP) received the highest customer satisfaction score among the nation’s public and… Read More
WASHINGTON — For the first time, the Food and Drug Administration is allowing marketing of a device as a preventive treatment for migraine headaches. The transcutaneous electrical nerve stimulation (TENS) device, marketed as Cefaly, also is the first to be… Read More